Literature DB >> 22029679

Idiopathic retroperitoneal fibrosis mimicking malignant lymphoma.

Eric F H van Bommel1, Mark de Mol, Anton W Langerak, Pieter J Westenend.   

Abstract

We present a case of atypical idiopathic retroperitoneal fibrosis (iRPF) presenting as a large pelvic tumor, for which it proved difficult to exclude T-cell malignant lymphoma. Histopathological examination of biopsy material showed collagenous tissue and fat with an exuberant and predominant T-cell infiltrate, largely consisting of CD4(+) cells expressing the IL-2 receptor-α chain (CD25). Focal plasma cells were negative for the immunoglobulin G4 (IgG4) isotype. T-cell receptor gene rearrangement (TRGR) pattern showed a Gaussian distribution, in keeping with a polyclonal T-cell population. Awareness of the sometimes exuberant and predominant T-cell infiltrate in iRPF should lead to earlier consideration of this disorder. This is particularly the case where there is an atypically localized and/or extensive mass, for which early exclusion of monoclonality with TRGR may provide helpful. Immunohistochemical findings suggest that CD4(+) CD25(+) cells, which are part of a naturally occurring population of regulatory T-cells, may be involved in the pathogenesis of iRPF.
© 2011 The Authors. Pathology International © 2011 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22029679     DOI: 10.1111/j.1440-1827.2011.02718.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  Fibrosing pericarditis in a patient with encapsulating peritoneal sclerosis.

Authors:  L Tonneijck; S Florquin; M R Korte; N H Schut
Journal:  Perit Dial Int       Date:  2012 Nov-Dec       Impact factor: 1.756

2.  Clinical significance of soluble interleukin-2 receptor measurement in patients with idiopathic retroperitoneal fibrosis.

Authors:  H H S Kharagjitsing; T R Hendriksz; M A Fouraux; T van Gelder; E F H van Bommel
Journal:  Int Urol Nephrol       Date:  2022-03-31       Impact factor: 2.266

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.